Smoking and age seem to have influence on patient response to first-line therapy of hidradenitis suppurativa, according to an institutional retrospective cohort study.
Secukinumab is superior to ustekinumab in clearing skin of individuals with moderate-to-severe plaque psoriasis through week 52, according to the results of the CLEAR study.
The use of cyclosporine may offer mortality benefit in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), a recent study has found.
Handwashing appears to have a minor contribution to Ebola transmission risk-related dermatitis, according to a new study, suggesting that communities dealing with Ebola should employ the handwashing method that is most appropriate to their situation and circumstance.
Patients with hidradenitis suppurativa (HS) have four to eight times higher prevalence (3.3 percent) of inflammatory bowel disease (IBD; Crohn’s disease or ulcerative colitis) than the general northern European population (0.41 to 0.74 percent), results of a multicentre, cross-sectional study have found.
Olumacostat glasaretil (OG) appears to be effective and is well tolerated in patients with moderate to severe facial acne vulgaris, suggesting the need for further development, according to a new study.
Adequately administered biological therapies, with proper follow-up, do not increase the risk for cancer development in patients with psoriatic arthritis (PsA), an observational study confirms.
The 10-year mortality is increased after hospitalization for atopic dermatitis compared with the general population, but significantly lower compared with psoriasis, a recent study has found.
Tofacitinib has a potential to treat severe alopaecia areata (AA), alopaecia totalis and alopaecia universalis, suggests a recent study.
Monitoring adalimumab levels and the presence of antiadalimumab antibodies does not appear to be useful for identifying treatment failures in patients with psoriasis. This is due to high variability of results, high prevalence of false-positives, and lack of association between adalimumab antibodies and clinical indexes and tumour necrosis factor α (TNFα) serum levels, according to a study.